About us
Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health.
Our stories
Everyone has a story about how mental health has affected them or someone they know. Our people bring their stories, and a wide range of backgrounds and skills, to Compass.
Our work
We want to give people living with mental health challenges better options.
News and views
Read our latest news and updates.
Join us
We are united by our commitment to improving mental health.
Our purpose
Watch our purpose video to find out who we are and what defines us.
News and views
Our collective understanding of mental illness is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
Find out how we use digital tools, including AI, software and mathematics, to better understand mental illness.
Investors
We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health.
COMP360 psilocybin treatment in TRD
We have completed the largest randomised, controlled, double-blind psilocybin treatment study ever done.
Impact
We are working to create positive impact by developing transformative therapies for those who are not helped by current treatments, by helping to build the mental health ecosystem of the future, and by acting responsibly as an organisation.
About us
Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health.
We are studying investigational psilocybin therapy (also known as psilocybin treatment), administered with psychological support, as a treatment for certain mental health conditions.
Psilocybin is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms’. We’ve developed an investigational, synthesised formulation of psilocybin, called COMP360, and are researching its effectiveness for certain serious mental health disorders, including treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa.
Re-enactment of a psilocybin therapy session
We are running a rigorous, global clinical development programme of investigational COMP360 psilocybin therapy for treatment-resistant depression.
The patient and therapist get to know each other, building a foundation of trust, so the patient can feel supported and at ease during their psilocybin session.
The patient lies down on a bed in a comfortable room, designed specifically for the session. They receive a dose of investigational COMP360 psilocybin in a capsule. During the experience, patients listen to a specially designed music playlist and wear an eye mask, to help them focus internally. The psilocybin experience typically lasts 6 to 8 hours. A therapist is present throughout the session.
Patients are encouraged to discuss their experiences of the psilocybin session.
Click on the icons below to read the relevant publications
This website is powered by renewable energy
Subscribe to receive the latest Compass news.
Compass © 2024. All rights reserved. Made by GIG.
The press releases and articles contained in this section are provided for historical purposes only. The information contained in each press release and article is accurate only as of the date each press release and article was originally issued. Compass disavows any obligation to update the information contained in such press releases and articles after the date of their issuance.
Compass does not control and is not responsible for the content on the website you are about to visit. Compass is providing this link as a convenience, and this link does not imply Compass endorsement of any material on the website you are about to visit. Do you wish to continue?
